Roche snags an FDA approval for an advanced melanoma drug cocktail — but it's up against some fierce competition
Roche’s PD-L1 inhibitor Tecentriq snagged an FDA approval to treat certain advanced melanoma patients in a three-drug cocktail, providing another option for patients with a typically poor prognosis.
In a Phase III IMspire150 study, Tecentriq combined with Cotellic (cobimetinib) and Zelboraf (vemurafenib) significantly beat a placebo mix in extending progression-free survival in BRAF V600 mutation-positive advanced melanoma patients. Participants on Tecentriq lived a median 15.1 months without worsening disease, compared to 10.6 months in patients on Cotellic, Zelboraf, and the placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.